Palvella says Phase 3 SELVA shows QTORIN rapamycin improves microcystic lymphatic malformations

• Palvella Therapeutics reported new data from its SELVA Phase 3 trial in microcystic lymphatic malformations, presented at the ISSVA World Congress 2026.
• The update showed broad clinical improvement across assessed patients, including meaningful reductions in hard-to-manage bleeding or leaking, with high patient-reported satisfaction.
• Independent blinded review supported disease stability before treatment, followed by clear improvement on therapy, reinforcing the trial’s baseline-controlled design.
• New TOIVA Phase 2 data in cutaneous venous malformations, also presented at the meeting, showed sustained improvements that strengthened with longer treatment duration.
• An NDA filing for QTORIN rapamycin in microcystic lymphatic malformations is planned for 2H 2026, with a Phase 3 start in cutaneous venous malformations targeted for 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605201630PRIMZONEFULLFEED9724180) on May 20, 2026, and is solely responsible for the information contained therein.